P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies
Public ClinicalTrials.gov record NCT06014762. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Open-Label, Multicenter, Phase 1 Study to Assess the Safety of P-CD19CD20-ALLO1 in Subjects With Selected Relapsed/Refractory B Cell Malignancies
Study identification
- NCT ID
- NCT06014762
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Poseida Therapeutics, Inc.
- Industry
- Enrollment
- 120 participants
Conditions and interventions
Conditions
- DLBCL
- DLBCL - Diffuse Large B Cell Lymphoma
- DLBCL Arising From Follicular Lymphoma
- DLBCL NOS
- DLBCL, Diffused Large B Cell Lymphoma
- Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
- Follicular Lymphoma Grade 3B
- High-grade B-cell Lymphoma
- Primary Mediastinal Large B-cell Lymphoma (PMBCL)
- Transformed Follicular Lymphoma (tFL)
Interventions
- P-CD19CD20-ALLO1 Biological
- Rimiducid Drug
Biological · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 15, 2024
- Primary completion
- Feb 28, 2029
- Completion
- Feb 28, 2041
- Last update posted
- May 6, 2026
2024 – 2041
United States locations
- U.S. sites
- 16
- U.S. states
- 14
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Loma Linda University Cancer Center | Loma Linda | California | 92354 | — |
| Cedars-Sinai Medical Center | Los Angeles | California | 90048 | — |
| Advent Health Orlando | Orlando | Florida | 32803 | — |
| Indiana University | Indianapolis | Indiana | 46202 | — |
| Our Lady of the Lake Hospital | Baton Rouge | Louisiana | 70808 | — |
| Ochsner Clinic Foundation | New Orleans | Louisiana | 70121 | — |
| Wayne State - Karmanos Cancer Institute | Detroit | Michigan | 48201 | — |
| NYU Grossman School of Medicine | New York | New York | 10016 | — |
| UNC Lineberger Comprehensive Cancer Center | Chapel Hill | North Carolina | 27599 | — |
| University of Cincinnati | Cincinnati | Ohio | 45206 | — |
| University of Oklahoma, Health Sciences Center | Oklahoma City | Oklahoma | 73104 | — |
| Oregon Health & Science University | Portland | Oregon | 97239 | — |
| Pennsylvania State University | Hershey | Pennsylvania | 17033 | — |
| Prisma Health - Upstate Cancer Institute | Greenville | South Carolina | 29605 | — |
| Vanderbilt University Medical Center | Nashville | Tennessee | 37232 | — |
| Baylor Scott & White Research Institute | Dallas | Texas | 75204 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06014762, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 6, 2026 · Synced May 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06014762 live on ClinicalTrials.gov.